- Home
- NGNE vs AVBH Comparison
NGNE vs AVBH Comparison
Compare NGNE & AVBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- AVBH
- Stock Information
- Founded
- NGNE 2003
- AVBH 2003
- Country
- NGNE United States
- AVBH United States
- Employees
- NGNE N/A
- AVBH N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- AVBH
- Sector
- NGNE Health Care
- AVBH
- Exchange
- NGNE Nasdaq
- AVBH Nasdaq
- Market Cap
- NGNE 325.3M
- AVBH 273.7M
- IPO Year
- NGNE N/A
- AVBH N/A
- Fundamental
- Price
- NGNE $19.95
- AVBH $25.05
- Analyst Decision
- NGNE Strong Buy
- AVBH Strong Buy
- Analyst Count
- NGNE 7
- AVBH 4
- Target Price
- NGNE $41.86
- AVBH $28.38
- AVG Volume (30 Days)
- NGNE 113.3K
- AVBH 67.4K
- Earning Date
- NGNE 08-11-2025
- AVBH 08-25-2025
- Dividend Yield
- NGNE N/A
- AVBH N/A
- EPS Growth
- NGNE N/A
- AVBH 61.05
- EPS
- NGNE N/A
- AVBH 3.07
- Revenue
- NGNE N/A
- AVBH $82,088,000.00
- Revenue This Year
- NGNE N/A
- AVBH $15.40
- Revenue Next Year
- NGNE N/A
- AVBH $16.94
- P/E Ratio
- NGNE N/A
- AVBH $8.17
- Revenue Growth
- NGNE N/A
- AVBH 21.72
- 52 Week Low
- NGNE $6.88
- AVBH $19.32
- 52 Week High
- NGNE $74.49
- AVBH $26.59
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- AVBH N/A
- Support Level
- NGNE $18.00
- AVBH N/A
- Resistance Level
- NGNE $19.93
- AVBH N/A
- Average True Range (ATR)
- NGNE 1.03
- AVBH 0.00
- MACD
- NGNE 0.01
- AVBH 0.00
- Stochastic Oscillator
- NGNE 55.71
- AVBH 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About AVBH Avidbank Holdings Inc. Common stock
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.